Davis JM - Search Results

1

Network meta-analyses should be the highest level of evidence in treatment guidelines.

Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Leucht S, et al. Among authors: davis jm. Eur Arch Psychiatry Clin Neurosci. 2016 Sep;266(6):477-80. doi: 10.1007/s00406-016-0715-4. Eur Arch Psychiatry Clin Neurosci. 2016. PMID: 27435721 Free article. No abstract available.

2

Old versus new: weighing the evidence between the first- and second-generation antipsychotics.

Davis JM, Chen N. Davis JM, et al. Eur Psychiatry. 2005 Jan;20(1):7-14. doi: 10.1016/j.eurpsy.2004.11.002. Eur Psychiatry. 2005. PMID: 15642438

3

Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours.

Leucht S, Davis JM. Leucht S, et al. Among authors: davis jm. Evid Based Ment Health. 2006 Feb;9(1):9. doi: 10.1136/ebmh.9.1.9. Evid Based Ment Health. 2006. PMID: 16436549 No abstract available.

4

Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

Leucht S, Engel RR, Bäuml J, Davis JM. Leucht S, et al. Among authors: davis jm. Schizophr Bull. 2007 Jan;33(1):183-91. doi: 10.1093/schbul/sbl025. Epub 2006 Aug 11. Schizophr Bull. 2007. PMID: 16905632 Free PMC article.

5

Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs.

Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Leucht S, et al. Among authors: davis jm. Neuropsychopharmacology. 2007 Sep;32(9):1903-10. doi: 10.1038/sj.npp.1301325. Epub 2007 Feb 7. Neuropsychopharmacology. 2007. PMID: 17287825

6

Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.

Stone JM, Davis JM, Leucht S, Pilowsky LS. Stone JM, et al. Among authors: davis jm. Schizophr Bull. 2009 Jul;35(4):789-97. doi: 10.1093/schbul/sbn009. Epub 2008 Feb 26. Schizophr Bull. 2009. PMID: 18303092 Free PMC article.

7

Has research informed us on the practical drug treatment of schizophrenia?

Davis JM, Leucht S. Davis JM, et al. Schizophr Bull. 2008 May;34(3):403-5. doi: 10.1093/schbul/sbn011. Epub 2008 Mar 11. Schizophr Bull. 2008. PMID: 18334508 Free PMC article. No abstract available.

8

Commentary on strategies for switching antipsychotics.

Davis JM, Leucht S. Davis JM, et al. BMC Med. 2008 Jun 30;6:18. doi: 10.1186/1741-7015-6-18. BMC Med. 2008. PMID: 18590521 Free PMC article.

9

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM. Leucht S, et al. Among authors: davis jm. Am J Psychiatry. 2009 Feb;166(2):152-63. doi: 10.1176/appi.ajp.2008.08030368. Epub 2008 Nov 17. Am J Psychiatry. 2009. PMID: 19015230

10

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Leucht S, et al. Among authors: davis jm. Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6. Lancet. 2009. PMID: 19058842

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,145 results

Search Page

Filters